Bristol-Myers Squibb: Home
 
Hepatitis C Compound News

Pipeline Asset Update for Daclatasvir (DCV; BMS-790052)
Discovered by Bristol-Myers Squibb through a genomics approach, daclatasvir, also known as BMS-790052 or DCV, is the first NS5A replication complex inhibitor to be investigated in hepatitis C clinical trials.
Conference on Retroviruses and Opportunistic Infections (CROI), 2012

BMS-790052 (NS5A inhibitor) and BMS-650032 (NS3 inhibitor)
BMS-790052 is an NS5A inhibitor and BMS-650032 is an NS3 protease inhibitor, both in development for the treatment of chronic hepatitis C virus (HCV) infection
American Association for the Study of Liver Diseases (AASLD), 2010

PEG-Interferon Lambda
A novel and potential first-in-class interferon in development for the treatment of hepatitis C virus (HCV) infection
American Association for the Study of Liver Diseases (AASLD), 2010

BMS-790052
Once-Daily NS5A Inhibitor Leads to High Rates of Extended Rapid Virologic Response in Treatment-Naïve HCV-Genotype 1 Subjects When Combined with Peginterferon and Ribavirin: A Phase 2a Trial
European Association for the Study of the Liver (EASL), April 2010

 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.
You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.